

HOWARD J. WEINSTEIN
MELISSA M. HUDSON
MICHAEL P. LINK
Editors

PEDIATRIC ONCOLOGY

Pediatric Lymphomas



Contents

1 Introduction and Historical Background: Pediatric Hodgkin Lymphoma

S.S. Donaldson

1.1	The Way It Was	1
1.2	Lessons from the Children	3
1.3	The Hidden Secrets – The Discovery of Late Effects	3
1.4	Current Optimal Management	4
	References	4

2 Biology and Pathology of Hodgkin's Disease

R.E. Hutchinson and A. Uner

2.1	History of Hodgkin's Disease Pathologic Classification	7
2.2	Lineage of Hodgkin Reed-Sternberg cells; B-cell phenotype	9
2.3	Some Evidence of Antigen-Presenting Function	10
2.4	Apoptosis	10
2.5	NF-kappaB	11
2.6	Jak/STAT Pathways	12
2.7	Tumor Necrosis Factor Receptor (TNFR) Family	12
2.8	Tumor Necrosis Factor Receptor-Associated Factors (TRAFs)	12
2.9	Cytokines and Chemokines	13
2.10	Cytogenetics	14
2.11	Gene Profile	14
2.12	Association with EBV	14
2.13	Pathology of Classical Hodgkin Lymphoma	16
2.14	Immunophenotype of Classical HRS cells	17
2.15	Flow Cytometry	18

2.16	Histologic Classification of CHL	19
2.16.1	Nodular Sclerosis HL	19
2.16.2	Mixed Cellularity HL	20
2.16.3	Nodular Lymphocyte Rich CHL	21
2.16.4	Lymphocyte Depleted HL	22
2.17	Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)	22
2.18	Hodgkin Lymphoma in the Setting of HIV Infection	23
2.19	Bone Marrow Involvement and Histologic Staging	23
2.20	Pathology of Relapse and Second Malignancy	24
2.21	Differential Diagnosis of HL	25
	References	27

3 Treatment of Pediatric Hodgkin Lymphoma

M.M. Hudson, C. Schwartz, and L.S. Constine

3.0	Introduction	35
3.1	Clinical Presentation	36
3.1.1	Systemic Symptoms	37
3.1.2	Laboratory Evaluation	37
3.1.3	Immunologic Status	38
3.2	Differential Diagnosis	39
3.3	Diagnostic Evaluation and Staging	40
3.4	Prognostic Factors	43
3.5	Combination Chemotherapy	45
3.6	Chemotherapy Alone Versus Combined Modality Therapy	49
3.7	Risk-Adapted Therapy	51
3.7.1	Treatment of Low-Risk Disease	51
3.7.2	Treatment of Intermediate- and High-Risk Disease	53
3.8	Principles of Radiation Therapy	54
3.8.1	Volume Considerations	56
3.8.2	Dose Considerations	58
3.8.3	Energy	59

3.9	Summary Recommendations for Primary Disease/Selection of Therapy	59
3.10	Acute Effects of Therapy	59
3.10.1	Chemotherapy Side-Effects.	59
3.10.2	Radiation Side-Effects	61
3.11	Future Directions	61
References		61

4 Treatment of Relapsed/Refractory Hodgkin Lymphoma

T.M. Trippett and A. Chen

4.1	Introduction	67
4.2	Strategies for Re-induction	67
4.2.1	Role of Re-induction Chemotherapy	68
4.2.2	Standard Re-induction with ICE	68
4.2.3	Re-induction with Ifosfamide/Vinorelbine (IV)	69
4.3	High-Dose Therapy	70
4.3.1	Immunomodulation as a Therapeutic Strategy to Augment High-Dose Therapy	71
4.3.2	Reduced-Intensity/Non-myeloablative Allogeneic Stem cell Transplantation.	72
4.4	Salvage Strategies Following Transplantation	72
4.4.1	Combination Chemotherapy with Gemcitabine/Vinorelbine (GEM/VRB)	73
4.4.2	Molecular Targeting of the NF- κ B Pathway.	74
4.4.2.1	Activation of NF- κ B.	74
4.4.2.2	Inhibition of NF- κ B Through Proteasome Inhibition	75
4.4.2.3	Adult Clinical Trials	76
4.4.2.4	Pediatric Clinical Trials.	77
4.4.2.5	Novel Retrieval Strategies Incorporating Proteasome Inhibition with Bortezomib	77
4.4.3	Targeted Immunotherapy Strategies.	77
4.4.3.1	Epstein-Barr Virus Directed Therapy	77
4.4.3.2	Monoclonal Antibodies Targeting Receptors Expressed in HL	78
4.4.3.3	Radiolabeled Immunoglobulin Therapy in HL	79
4.5	Future Considerations	79
References		79

5 Non-Hodgkin's Lymphoma: Introduction and Historical Background

S.B. Murphy

5.1	Introduction	85
5.2	The Early Era, Pre-1970	86
5.3	The Latter Era, Post-1970s	86
References		88

6 Biology and Pathology of Pediatric Non-Hodgkin Lymphoma

S.L. Perkins and S.W. Morris

6.1	Introduction	91
6.2	Non-Hodgkin Lymphoma	91
6.3	Pathologic Analysis.	93
6.3.1	Morphology	93
6.3.2	Immunophenotypic Analysis.	94
6.3.3	Molecular and Cytogenetic Analysis	95
6.3.4	WHO Classification of Hematolymphoid Tumors.	100
6.4	Molecular Pathogenesis of Pediatric NHL	101
6.5	Burkitt Lymphomas	101
6.5.1	Pathology.	101
6.5.2	Biology and Molecular Mechanisms	104
6.6	Diffuse Large B-Cell Lymphomas	107
6.6.1	Pathology.	107
6.6.2	Biology and Molecular Mechanisms	109
6.7	Anaplastic Large-Cell Lymphoma	112
6.7.1	Pathology.	112
6.7.2	Biology and Molecular Mechanisms	117
6.8	Lymphoblastic Lymphoma.	119
6.8.1	Pathology.	119
6.8.2	Biology and Molecular Mechanisms	121
References		127

7 B-Cell Lymphoma/Burkitt Lymphoma

I. Magrath

7.1	Introduction	142
7.2	Diagnosis and Imaging	142
7.2.1	Burkitt Lymphoma	142
7.2.2	Diffuse Large B-cell Lymphoma	143
7.2.3	Burkitt-like Lymphoma	144
7.2.4	HIV-Associated B-cell Lymphomas	144
7.2.5	Imaging Studies.	144

7.3	Clinical Features	146
7.4	Staging	148
7.4.1	Staging Procedures	150
7.5	Treatment	151
7.5.1	Early Studies in Africa	151
7.5.2	Non-Cross-Resistant Drugs and Combination Therapy	152
7.5.3	Therapy Directed Towards CNS Disease	154
7.5.4	Early Studies in the USA	154
7.5.5	Comparison with Leukemia Treatment	155
7.5.6	Critical Components of Modern Treatment Protocols	155
7.5.6.1	Basic Drugs	155
7.5.6.2	High-Dose MTX	156
7.5.6.3	The Role of Additional Drugs	156
7.5.6.4	Dose Density	157
7.5.6.5	Risk Adaptation	157
7.5.6.6	Prevention of CNS Disease	159
7.5.6.7	Treatment of DLBCL with Different Regimens	160
7.5.6.8	Role of Surgery	160
7.5.6.9	Role of Radiation	161
7.5.6.10	Tumor Lysis Syndrome	162
7.6	Prognostic Factors	163
7.6.1	Tumor Burden and Stage	163
7.6.2	Rapidity of Response	164
7.6.3	Age and Sex	164
7.6.4	Histology	164
7.6.5	Molecular Characteristics	165
7.7	Outcome	165
7.8	Management of Relapse	166
7.9	Follicle Center Cell and Marginal Zone Lymphomas	167
7.10	Future Prospects	167
	References	168

8 Anaplastic Large-Cell Lymphoma

A. Reiter

8.1	Introduction	175
8.2	Diagnosis and Imaging	177
8.3	Clinical Features	178
8.4	Staging	181
8.5	Treatment and Outcome	181
8.5.1	Stratification of Treatment Intensity	185
8.5.2	CNS Prophylaxis and CNS Therapy	185
8.5.3	Role of Local Therapy Modalities and Pattern of Therapy Failure	186
8.6	Prognostic Factors	187
8.7	Management of Relapse	189
8.8	Future Prospects	190
	References	192

9 Precursor B and Precursor T-Cell Lymphoblastic Lymphoma

J.T. Sandlund

9.1	Introduction	199
9.2	Diagnosis and Imaging	199
9.2.1	Diagnosis	199
9.2.2	Imaging/Staging	201
9.3	Clinical Features	202
9.4	Treatment	202
9.4.1	Initial Management	202
9.4.2	Treatment Overview	203
9.4.2.1	Limited Stage Disease	203
9.4.2.2	Advanced Stage Disease	204
9.4.2.3	Central Nervous System Prophylaxis and Treatment	205
9.5	Prognostic Factors	208
9.6	Outcome	208
9.7	Management of Relapse	208
9.8	Future Prospects	208
	References	210

10 Cutaneous T-Cell Lymphomas and Rare T-Cell Non-Hodgkin Lymphomas

M.E. Kadin

10.1	Introduction	215
10.2	Mycosis Fungoides and Sezary Syndrome	216
10.2.1	Clinical Features	216
10.2.2	Pathology	217
10.2.3	Immunophenotype	218
10.2.4	Genetic Features	218
10.2.5	Prognosis	219
10.2.6	Therapy	220
10.3	CD30+ Cutaneous T-Cell Lymphomas Including Lymphomatoid Papulosis	221
10.4	Lymphomatoid Papulosis	221
10.4.1	Clinical Features	221
10.4.2	Pathology	222
10.4.3	Immunophenotype	223
10.4.4	Genetic Features	223
10.4.5	Prognosis	223
10.5	Primary Cutaneous Anaplastic Large-cell Lymphoma	224
10.5.1	Clinical Features	224
10.5.2	Pathology	224
10.5.3	Differential Diagnosis	224
10.5.4	Immunophenotype	225
10.5.5	Genetic Features	225
10.5.6	Therapy	225

10.6	Subcutaneous Panniculitis-like T-Cell Lymphoma	225
10.6.1	Clinical Features	226
10.6.2	Pathology	226
10.6.3	Immunophenotype	226
10.6.4	Genetic Features	227
10.6.5	Therapy	227
10.7	Hepatosplenic T-Cell Lymphoma	227
10.7.1	Clinical Features	227
10.7.2	Pathology	227
10.7.3	Immunophenotype	227
10.7.4	Genetic Features	227
10.7.5	Therapy	228
References		228

11 Lymphoproliferative Disorders Related to Immunodeficiencies

T.G. Gross and B. Shiramizu

11.1	Introduction	233
11.2	Epstein-Barr Virus	234
11.3	Post-transplant Lymphoproliferative Disease	236
11.3.1	PTLD Following Blood or Marrow Transplantation	239
11.3.2	PTLD Following Solid Organ Transplantation	240
11.4	HIV-Related Malignancies	242
11.5	Lymphoproliferative Disease in Primary Immunodeficiencies	246
11.6	Summary	250
References		250

12 Late Effects Following Lymphoma Treatment

D.L. Friedman and A.T. Meadows

12.1	Introduction	259
12.2	Second Malignant Neoplasms	260
12.3	Neurocognitive	261
12.4	Cardiovascular	261
12.5	Pulmonary	263
12.6	Bone and Body Composition	264
12.7	Endocrine	264
12.7.1	Thyroid Gland	264
12.8	Reproductive Endocrine	265
12.8.1	Male Gonadal Function	265
12.8.2	Female Gonadal Function	265
12.8.3	Reproduction	266
12.9	Dental	267
12.10	Spleen	267
12.11	Psychosocial	268
12.12	Mortality	268
12.13	Monitoring for Late Effects	269
12.14	Research Challenges for Lymphoma Survivors	269
12.15	Future Directions	273
References		274

Subject Index	281
--------------------------------	-----